DREAMM 4: Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
Study Details
Study Description
Brief Summary
This is a phase I/II, single arm, open label, two-part study that will assess safety, tolerability and clinical activity of GSK2857916 given in combination with a programmed cell death-1 (PD-1) inhibitor pembrolizumab in subjects with RRMM. This study will enroll adult subjects with RRMM, who have undergone stem cell transplant or who are considered transplant ineligible. Part 1 is a dose escalation phase to evaluate the safety and tolerability of escalating doses of GSK2857916 in combination with 200 milligrams (mg) pembrolizumab to establish the recommended phase 2 dose (RP2D). The following dose levels of GSK2857916 are planned to be studied: 2.5 milligrams per kilograms (mg/kg) (dose level [DL] 1) and 3.4 mg/kg (DL2). Part 2 is a dose expansion cohort. Once the RP2D has been identified, an expansion cohort will open for enrolment to confirm the safety profile and to evaluate the clinical activity of the combination. Up to 40 evaluable subjects will be enrolled in this two-part study (up to 12 in Part 1, and 28 in Part 2).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part 1: Dose escalation Subjects will receive belantamab mafodotin at escalating doses of 2.5 milligrams per kilograms (mg/kg) and 3.4 mg/kg along with 200 mg pembrolizumab via intravenous (IV) infusion on Day 1 of each 21-day cycle to establish RP2D. There will be maximum of 35 cycles of combination treatment. |
Drug: belantamab mafodotin
belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
Drug: Pembrolizumab
Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
|
| Experimental: Part 2: Expansion cohort Subjects will receive belantamab mafodotin at RP2D along with 200 mg pembrolizumab via IV infusion on Day 1 of each 21-day cycle. There will be maximum of 35 cycles of combination treatment. |
Drug: belantamab mafodotin
belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
Drug: Pembrolizumab
Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
|
Outcome Measures
Primary Outcome Measures
- Part 1: Percentage of subjects with adverse events (AEs) and serious adverse events (SAEs) [Up to 2 years]
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function.
- Part 1: Number of subjects with abnormal hematology parameters [Up to 2 years]
Blood samples will be collected to measure platelets, white blood cell (WBC count), red blood cell (RBC) count, reticulocyte count, hemoglobin, hematocrit, RBC indices, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), basophils, eosinophils, lymphocytes, monocytes and neutrophils.
- Part 1: Number of subjects with abnormal clinical chemistry parameters [Up to 2 years]
Blood samples will be collected to measure blood urea nitrogen (BUN), creatinine, fasting glucose, sodium, magnesium, potassium, chloride, calcium, phosphorus, troponin, uric acid, triglycerides, Aspartate aminotransferase (AST), ALT, alkaline phosphatase, total and direct bilirubin, albumin, creatinine kinase (CK), total carbon dioxide (CO2)/bicarbonate and total protein.
- Part 1: Number of subjects with abnormal urinalysis results [Up to 2 years]
Samples will be collected to measure specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick method.
- Part 1: Number of subjects with abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP) [Up to 2 years]
The number of subjects with abnormal SBP and DBP will be measured in a semi-supine position after 5 minutes rest.
- Part 1: Number of subjects with abnormal pulse rate [Up to 2 years]
The number of subjects with abnormal pulse rate will be measured in a semi-supine position after 5 minutes rest.
- Part 1: Number of subjects with abnormal body temperature [Up to 2 years]
The number of subjects with abnormal body temperature will be measured in a semi-supine position after 5 minutes rest.
- Part 1: Number of subjects with dose limiting toxicities (DLTs) [Up to 21 days]
A DLT is an AE that is considered by the investigator to be clinically relevant and attributed to the study therapy during the 21 day DLT period and meets at least one of the criteria: any Grade 4 and 3 non-hematologic toxicity, any Grade 3 or greater non-hematologic laboratory value, hematologic toxicity lasting >=7 days, except Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia associated with clinically significant bleeding. Grade 3 or greater febrile neutropenia lasting >48 hours despite adequate treatment, Nephrotoxicity requiring dialysis, Liver toxicity, prolonged delay (>14 days) in initiating Cycle 2 due to any treatment (pembrolizumab or GSK2857916) related toxicity, any treatment-related toxicity that causes discontinuation of treatment during Cycle 1, any other toxicity considered to be dose-limiting that occurs beyond 21 days and any other event which in the judgment of the investigator and GlaxoSmithKline Medical Monitor is considered to be a DLT.
- Part 2: Overall Response Rate [Up to 2 years]
Overall Response rate is defined as the percentage of subjects with a confirmed partial response (PR) or better (i.e., PR, very good partial response [VGPR], complete response [CR] and stringent complete response [sCR]), according to the International Myeloma Working Group (IMWG) Response Criteria.
Secondary Outcome Measures
- Part 1: Overall response rate [Up to 2 years]
Overall Response rate is defined as the percentage of subjects with a confirmed PR or better (i.e., PR, VGPR, CR and sCR), according to the IMWG Response Criteria.
- Part 1: AUC (0-tau) for total monoclonal antibody (mAb) following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 1: AUC (0-168 hours [h]) for cysteine maleimidocaproyl monomethyl auristatin F (cys-mcMMAF) following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 1: Maximum concentration (Cmax) following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 1: Time of Cmax (tmax) following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 1: Last time point where the concentration is above the limit of quantification (tlast) following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 1: Concentration at trough (Ctrough) following IV administration of GSK2857916 in combination with pembrolizumab for Cycles 2 and 5 [Pre-dose (prior to start of infusion) and end of infusion after GSK2857916 and pembrolizumab of Cycles 2 and 5 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 1: Ctrough following IV administration of GSK2857916 for Cycles 8 and 11 [Pre-dose (prior to start of infusion) and end of infusion after GSK2857916 of Cycles 8 and 11 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously.
- Part 1: Ctrough following IV administration of GSK2857916 for Cycle 14 and every 3 Cycles until Cycle 35 [Pre-dose (prior to start of infusion) after GSK2857916 of Cycles 14 and every 3 Cycles until Cycle 35 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously.
- Part 1: End of infusion concentration following IV administration of GSK2857916 in combination with pembrolizumab [Pre-dose (prior to start of infusion) and end of infusion after GSK2857916 and pembrolizumab of Cycles 2, 5, 8, 11, 14 and every 3 Cycles until Cycle 35 (Each cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 1: Number of subjects with positive anti-drug antibodies (ADAs) against GSK2857916 [Up to 2 years]
Samples will be taken from all the subjects to analyze for the presence of ADAs using validated immunoassays.
- Part 1: Titers of ADAs against GSK2857916 [Up to 2 years]
Samples will be taken from all the subjects to analyze for the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.
- Part 2: Number of subjects with AEs and SAEs [Up to 2 years]
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment or is associated with liver injury and impaired liver function.
- Part 2: Number of subjects with abnormal hematology parameters [Up to 2 years]
Blood samples will be collected to measure platelets, WBC count, RBC count, reticulocyte count, hemoglobin, hematocrit, , RBC indices, MCV, MCH, MCHC, basophils, eosinophils, lymphocytes, monocytes and neutrophils.
- Part 2: Number of subjects with abnormal clinical chemistry parameters [Up to 2 years]
Blood samples will be collected to measure BUN, creatinine, fasting glucose, sodium, magnesium, potassium, chloride, calcium, phosphorus, troponin, uric acid, triglycerides, AST, ALT, alkaline phosphatase, total and direct bilirubin, albumin, CK, Total CO2/bicarbonate and total protein.
- Part 2: Number of subjects with abnormal urinalysis results [Up to 2 years]
Samples will be collected to measure specific gravity, pH, glucose, protein, blood and ketones by dipstick method.
- Part 2: Number of subjects with abnormal SBP and DBP [Up to 2 years]
The number of subjects with abnormal SBP and DBP will be measured in a semi-supine position after 5 minutes rest.
- Part 2: Number of subjects with abnormal pulse rate [Up to 2 years]
The number of subjects with abnormal pulse rate will be measured in a semi-supine position after 5 minutes rest.
- Part 2: Number of subjects with abnormal body temperature [Up to 2 years]
The number of subjects with abnormal body temperature will be measured in a semi-supine position after 5 minutes rest.
- Part 2: Number of subjects with ocular findings on ophthalmic exam [Up to 2 years]
A full ophthalmic examination for all subjects will be conducted for any abnormal ocular findings.
- Part 2: Clinical benefit rate [Up to 2 years]
Clinical benefit rate is defined as the percentage of subjects with a confirmed minimal response (MR) or better according to the IMWG Response Criteria.
- Part 2: Duration of response [Up to 2 years]
Duration of response is defined as the time from first documented evidence of PR or better, to the time when disease progression (PD) is documented per IMWG response criteria; or death due to PD occurs among subjects who achieve an overall response, i.e. confirmed PR or better.
- Part 2: Time to response [Up to 2 years]
Time to response is defined as the time between the date of first dose and the first documented evidence of response (PR or better) among subjects who achieved a confirmed response of PR or better.
- Part 2: Time to best response [Up to 2 years]
Time to best response is defined as the time between the date of first dose and the first best documented response (PR or better) among subjects who achieved a confirmed response of PR or better.
- Part 2: Progression-free survival [Up to 2 years]
Progression-free survival is defined as the time from first dose until the earliest date of PD per IMWG response criteria, or death due to any cause.
- Part 2: Time to disease progression [Up to 2 years]
Time to disease progression is defined as the time from first dose until the earliest date of PD per IMWG response criteria, or death due to PD.
- Part 2: Overall Survival [Up to 2 years]
Overall Survival is defined as the time from first dose until death due to any cause.
- Part 2: AUC (0-tau) for total mAb following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 2: AUC (0-168 h) for cys-mcMMAF following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 2: Cmax following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 2: tmax following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 2: Tlast following IV administration of GSK2857916 in combination with pembrolizumab after the first dose [Pre-dose (prior to start of infusion), end of infusion after GSK2857916 and pembrolizumab; 4, 9 or 24 hours after GSK2857916 start of infusion of Cycle 1 Day 1; Anytime on Day 4, Anytime between Days 8 of Cycle 1 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 2: Ctrough following IV administration of GSK2857916 in combination with pembrolizumab for Cycles 2 and 5 [Pre-dose (prior to start of infusion) and end of infusion after GSK2857916 and pembrolizumab of Cycles 2 and 5 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 2: Ctrough following IV administration of GSK2857916 for Cycles 8 and 11 [Pre-dose (prior to start of infusion) and end of infusion after GSK2857916 of Cycles 8 and 11 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously.
- Part 2: Ctrough following IV administration of GSK2857916 for Cycle 14 and every 3 Cycles until Cycle 35 [Pre-dose (prior to start of infusion) after GSK2857916 of Cycle 14 and every 3 Cycles until Cycle 35 (Each Cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously.
- Part 2: End of infusion concentration following IV administration of GSK2857916 in combination with pembrolizumab [Pre-dose (prior to start of infusion) and end of infusion after GSK2857916 and pembrolizumab of Cycles 2, 5, 8, 11, 14 and every 3 Cycles until Cycle 35 (Each cycle will be of 21 days)]
Blood samples will be collected for PK analysis of GSK2857916 when administered intravenously in combination with pembrolizumab.
- Part 2: Number of subjects with positive ADAs against GSK2857916 [Up to 2 years]
Samples will be taken from all the subjects to analyze for the presence of ADAs using validated immunoassays.
- Part 2: Titers of ADAs against GSK2857916 [Up to 2 years]
Samples will be taken from all the subjects to analyze for the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.
Eligibility Criteria
Criteria
Inclusion criteria:
-
Provide signed written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
-
Male or female, 18 years or older (at the time consent is obtained).
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
-
Subjects must: have histologically or cytologically confirmed diagnosis of Multiple myeloma (MM), as defined by IMWG, 2014 and has undergone stem cell transplant or is considered transplant ineligible, and has been treated with at least 3 prior lines of prior anti-myeloma treatments including an immunomodulatory imide drug (IMiD) (eg. lenalidomide or pomalidomide), a proteasome inhibitor (eg. bortezomib, ixazomib or carfilzomib) and an anti-CD38 antibody alone or in combination. Line of therapy are defined by consensus panel of the International Myeloma Workshop, Has measurable disease defined as one the following: a) Serum M-protein >=0.5 grams per deciliter (g/dL) (>=5 grams per liter [g/L]). b) Urine M-protein ≥200 mg/24h. c) Serum Free light chain (FLC) assay: Involved FLC level ≥10 milligrams per deciliter (mg/dL) (≥100 milligrams per liter [mg/L]) and an abnormal serum free light chain ratio (<0.26 or
1.65).
-
Subjects with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: a) transplant was > 100 days prior to study enrolment. b) no active infection(s). c) subject meets the remainder of the eligibility criteria.
-
Adequate organ system functions as defined by the laboratory assessments.
-
All prior treatment-related toxicities (defined by National Cancer Institute-Common Toxicity Criteria for Adverse Events [NCI-CTCAE], version 4.03, 2010) must be <= Grade 1 at the time of enrolment except for alopecia and Grade 2 neuropathy.
-
A female subject is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of childbearing potential (WOCBP) OR is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), preferably with low user dependency, during the intervention period and for at least 120 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
-
Male subjects are eligible to participate if they agree to the following during the intervention period and for at least 140 days after the last dose of study intervention. Male subjects should refrain from donating sperm, plus, either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of <1% per year when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
Exclusion criteria:
A subject will NOT be eligible for inclusion in this study if any of the following criteria apply:
-
Systemic anti-myeloma therapy or an investigational drug <=14 days or five half-lives, whichever is shorter, preceding the first dose of study drug
-
Plasmapheresis within 7 days prior to the first dose of study drug
-
Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs
-
Has received prior therapy with an anti-PD-1, anti-Programmed cell death Ligand 1 (PD-L1), or anti-Programmed cell death Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune related adverse event (irAE)
-
Current corneal epithelial disease except mild punctate keratopathy
-
Any major surgery within the last four weeks prior to the first dose of study therapy
-
Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect subject's safety). Subjects with isolated proteinuria resulting from MM are eligible, provided they fulfil criteria as per adequate organ system function mentioned under inclusion criteria.
-
Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.
-
Has received prior radiotherapy within 2 weeks of start of study therapy. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (<=2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
-
History of (non-infectious) pneumonitis that required steroids, or current pneumonitis
-
Current active liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
-
Malignancies other than disease under study are excluded, except for any other malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (RRMM). Subjects with curatively treated non-melanoma skin cancer are allowed.
-
Has known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study therapy
-
Evidence of cardiovascular risk including any of the following: a) corrected for heart rate by Fridericia's formula (QTcF) interval ≥470 msecs. b) Evidence of current clinically significant uncontrolled arrhythmias; i. including clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd degree atrioventricular (AV) block. c) History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within six months of Screening. d) Class III or IV heart failure as defined by the New York Heart Association functional classification system. e) Uncontrolled hypertension. f) Presence of cardiac pacemaker (or defibrillator) with a predominantly ventricular paced rhythm, limiting ECG/QTcF analysis. g) Abnormal cardiac valve morphology (>=Grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
-
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2857916 or pembrolizumab, or any of the components of the study treatment.
-
Pregnant or lactating female.
-
Known active infection requiring antibiotic, antiviral, or antifungal treatment.
-
Known Human Immunodeficiency Virus (HIV) infection.
-
Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study treatment
-
Positive hepatitis C antibody test result or positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.
-
Has received a live-virus vaccination within 30 days of planned start of study therapy.
-
Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
-
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other chronic form of immunosuppressive therapy within 7 days prior the first dose of study therapy.
-
Has known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.
-
Has had an allogenic tissue/solid organ transplant
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | GSK Investigational Site | Atlanta | Georgia | United States | 30322 |
| 2 | GSK Investigational Site | Indianapolis | Indiana | United States | 46202 |
| 3 | GSK Investigational Site | Charlotte | North Carolina | United States | 28204 |
| 4 | GSK Investigational Site | Madison | Wisconsin | United States | 53792 |
| 5 | GSK Investigational Site | Calgary | Alberta | Canada | T2N 2T9 |
| 6 | GSK Investigational Site | Toronto | Ontario | Canada | M5G 2M9 |
| 7 | GSK Investigational Site | Hannover | Niedersachsen | Germany | 30625 |
| 8 | GSK Investigational Site | Berlin | Germany | 12200 | |
| 9 | GSK Investigational Site | Hamburg | Germany | 20246 | |
| 10 | GSK Investigational Site | Badalona | Spain | 08916 | |
| 11 | GSK Investigational Site | Pozuelo De Alarcón/Madrid | Spain | 28223 | |
| 12 | GSK Investigational Site | Salamanca | Spain | 37007 |
Sponsors and Collaborators
- GlaxoSmithKline
- Merck Sharp & Dohme LLC
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 205207
- KEYNOTE PN489